Salesforce Als-Con-201 Practice Exam Questions & Answers

Option B is correct. In Salesforce Life Sciences Cloud Remote Engagement, the standard object used for the executed video engagement details is the remote-call/video-call record. Salesforce's Life Sciences Developer Guide includes the VideoCall object for Remote Engagement and describes it as storing important information about the remote engagement, including its relationship to the associated provider visit. This aligns with the requirement to verify that the remote interaction occurred and review engagement metrics after the call concludes.

Provider Visit is related to the customer interaction and can represent the overall HCP visit context, but it is not the most precise object for the executed video-call details. The remote engagement session itself needs its own object because it can store video-specific information such as call status, timing, service details, and other remote-session metadata.

Option C, Video Log, is not the correct standard Life Sciences object name in the Salesforce documentation. ''Video Log'' sounds like a generic audit or logging object, but the documented Remote Engagement object is VideoCall. Since the answer options use ''Remote Call'' rather than ''VideoCall,'' Remote Call is the closest and intended answer for the standard remote engagement execution record. Therefore, the consultant should use the Remote Call/VideoCall record to review the executed Remote Engagement details.

Option C is correct because the requirement is strict enforcement. Salesforce Help for Sample Limit Template types states that when the enforcement type is Error, distributions are blocked after limits are met. This directly matches the legal requirement in the question: the field sales rep must be prevented from submitting the visit when the disbursement quantity exceeds the allowed limit.

A controlled substance requires a hard compliance stop rather than a soft business warning. Setting the Limit Enforcement Type to Error ensures that the rep receives an error message and must correct the sample quantity before continuing. This protects the company from noncompliant disbursements and supports controlled sampling governance.

Option A is incorrect because Warning is a soft-limit behavior. A warning may alert the rep that the limit has been exceeded, but it allows the rep to proceed. That does not meet the requirement to strictly prevent the transaction. Option B is also not the best answer because ''Block'' is not the documented Limit Enforcement Type in the sample-limit template options shown in Salesforce's Life Sciences sample limit resources. The documented strict enforcement behavior is Error. Therefore, for controlled substances or any legally required hard stop, the consultant should configure the Sample Limit Template with Limit Enforcement Type set to Error.

Option B is correct because Presentation Page Product is the standard Life Sciences Cloud object that links presentation content to products. Salesforce's Life Sciences Cloud Developer Guide states that PresentationPageProduct represents the link between a presentation page and a product, and may also include a connection to product guidance or product messages. This directly matches the requirement to link Immunexis to specific presentation pages or slide content so analytics can identify which products were detailed during visits.

Salesforce's Intelligent Content data model also includes Presentation, Presentation Linked Page, Presentation Page, Presentation Page Product, Product2, Life Science Marketable Product, Provider Visit, and visit-detailing objects. This confirms that Presentation Page Product is part of the standard content and detailing analytics architecture for Life Sciences Customer Engagement.

Option A, Presentation Linked Page, is not the best answer because it links pages within presentation structure, but it does not specifically represent the product association. Option C, Product Media Link, is not the documented standard object for connecting Life Sciences presentation pages to products. Salesforce also provides a Presentation Page Product API resource for creating or updating product and guidance associations for a presentation page, reinforcing that this is the intended object.

Therefore, the consultant should use Presentation Page Product.

The correct answer is B because Life Sciences Cloud supports configuring quick actions for the mobile app through the Admin Console. Salesforce Help for Medical Insights states that Medical Insights can be made available to users in the Life Sciences mobile app so users can view their own insights and insights shared with them. Salesforce Help also describes Quick and Custom Action Management as the way to simplify user experiences in Salesforce and the Life Sciences for Customer Engagement mobile app by leveraging quick actions and custom actions.

The requirement is not merely to expose the Medical Insights tab. The rep must be able to quickly report a medical insight while managing a visit on an iPad. Configuring the Create Medical Insights quick action in the Admin Console makes the action available in the mobile workflow where reps need it. This supports fast, in-context capture of field observations during a visit.

Option A is incorrect because creating a custom action and custom flow adds unnecessary complexity when the standard quick action can be configured declaratively. Option C is also not the best answer because editing the Visit page layout and adding a generic standard action may not make the action available correctly in the Life Sciences mobile app experience. The Admin Console is the correct configuration point for mobile quick actions. Therefore, the consultant should configure the Create Medical Insights quick action using the Admin Console.

Option C is correct because the requirement is product-specific and should be configured through Product Discussion Settings, not through a generic page-layout or Visit validation rule. Salesforce's Life Sciences Cloud Visit Management data model includes Provider Visit Product Discussion as the object that represents products discussed during a visit, including key details about the product brand, therapeutic area, and related information. Salesforce also documents ProviderVisitProdDiscussion as representing additional notes or information about products discussed during a healthcare provider visit.

The question asks for a configuration that applies when a specific product, such as Immunexis, is discussed. Enabling Require Discussion in Product Discussion Settings for the product record is the most targeted standard configuration because it ties the requirement to that product's visit discussion behavior.

Option A is not the best answer because a custom validation rule on Visit would have to inspect related product-discussion records and could become complex or unreliable for mobile visit submission behavior. Option B is also insufficient because making a Comments field required on the page layout would apply based on the layout, not specifically when Immunexis is discussed. It also would not necessarily enforce product-specific discussion requirements across all relevant visit submission paths. Therefore, the consultant should enable Require Discussion in Product Discussion Settings for the Immunexis product record.

The correct answer is A because Salesforce's Remote Engagement setup guidance for Life Sciences Cloud specifically identifies the Experience Cloud site as the place where language support is configured for remote engagement experiences. Salesforce Help for creating an Experience Cloud site for Remote Engagement states that, for language support, the administrator should select Components and drag the Language Selector component to the page. This directly supports the requirement for HCPs to review and accept terms and conditions in multiple languages when joining remote visits.

Remote Engagement involves an HCP-facing experience, not only a sales-rep mobile action. The terms and conditions are presented through the Experience Cloud site used for the remote session, so the language-selection capability must be available there. Adding the Language Selector lets the HCP choose the appropriate language in the site experience before reviewing the terms.

Option B is incorrect because configuring the Start Remote Session quick action may help reps launch or manage remote sessions, but it does not provide the HCP-facing multilingual site control required for terms and conditions. Option C is also incorrect because a survey can collect feedback or preferences, but it is not the Salesforce-recommended way to localize the terms-and-conditions experience. The correct configuration is to add the Language Selector component to the Experience Cloud site.

Data Use Purpose is the correct answer. In Salesforce Life Sciences Cloud Consent Management, a Communication Subscription represents a specific subscription, such as a newsletter, and the consent model must also connect that subscription to the business purpose and relevant Life Sciences product. Salesforce's Life Sciences Help documentation specifically describes creating a Data Use Purpose record to associate a Life Sciences Marketable Product with a Communication Subscription. That directly matches the scenario: ''Immunology Monthly'' is the Communication Subscription, and ''Immunexis'' is the product record that must be linked for consent capture.

Engagement Channel Type is not correct because it represents the channel through which the HCP can be contacted, such as email, SMS, or other communication methods. It defines the communication channel, not the relationship between a subscription and a marketable product. Communication Subscription Consent is also not correct because it represents an individual customer's or HCP's consent preference for a subscription. In other words, that record is created or updated when the HCP opts in or opts out; it is not the setup record used to link the newsletter subscription to the product. Salesforce's Life Sciences standard object documentation also describes Communication Subscription Consent as representing a customer's consent to a communication subscription, reinforcing that it stores the HCP's consent outcome rather than the product-subscription configuration.